I would prefer if the news release also indicated the dosing has ended and last patient visits have commenced. But publicly stating that they have reached 250 events is a good start! Along those lines, I sent Sarah a question this afternoon, but haven't heard back yet.

"Thank you for guiding me to the January Corporate presentation for the most up to date information. However, I notice a discrepancy in the slides regarding the target number of events.

Slide 17 states "The study is an event-based trial and continues until 250 narrowly defined MACE events have occurred"

Slide 20 states "Trial completion – trial to continue until 250+ narrow MACE events have occurred"

Can you please clarify this discrepancy? Does reaching 250 events trigger the end of dosing, or does Resverlogix have the option to continue dosing past the 250 event mark?"